Teva and Trump Administration Announce Intent to Reach Agreement on Affordable Medicines and Supply Chain Security for U.S. Medicaid Patients
核心洞察
Teva Pharmaceuticals and the Trump Administration announced a shared commitment to lower the cost of select medicines for American patients covered by Medicaid.
If finalized, the agreement would align U.S. Medicaid pricing for select medicines with leading developed markets through the GENEROUS framework.
The deal would include a prospective Most-Favored-Nation (MFN) commitment for future innovative product launches and a dedicated reserve of certain active pharmaceutical ingredients (API).
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced on Aug. 31, 2026 a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, the agreement will support continued investment in scientific innovation and pharmaceutical manufacturing capabilities.
"Teva appreciates the opportunity to work with President Trump and his Administration to expand access and affordability for patients today while enabling continued investment in medicines patients need tomorrow," said Chris Fox, President, Teva USA. "Teva built its business around delivering affordable medicines to Americans, and we share the Administration's commitment to improve access to more affordable medicines while investing in scientific innovation and domestic manufacturing capabilities in the U.S."
Framework for Pricing Alignment and Supply Chain Security
Teva remains in active discussions with the Trump Administration to strike a deal anchored in all four of the President's drug pricing priorities. If an agreement is reached, Teva would align U.S. Medicaid pricing for select medicines with pricing in leading developed markets through the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) framework.
The agreement also would include a prospective Most-Favored-Nation (MFN) commitment for applicable future innovative product launches. Additionally, Teva has offered a dedicated reserve of certain active pharmaceutical ingredients (API) in support of public health needs and continued investment into U.S. pharmaceutical manufacturing capabilities. Conditions of the negotiation to reach a final agreement remain confidential.
Company Context
Teva Pharmaceutical Industries Ltd. is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, the company has innovated in the fields of neuroscience and immunology while providing complex generic medicines, biosimilars and pharmacy brands worldwide.
The announcement notes that the agreement is subject to substantial risks and uncertainties, including the effects of reforms in healthcare regulation and related reductions in pharmaceutical pricing, reimbursement and coverage, as well as U.S. Executive Orders issued in April and May 2025 intended to reduce the prices paid for prescription medicines, including most-favored-nation pricing and related regulatory efforts.